{"schema_version":"alpha-company-profile-public-v2","slug":"bicara-therapeutics-inc","canonical_url":"https://registry.alpha.ac/companies/bicara-therapeutics-inc","published_on":"2026-09-21T04:46:04.996939+00:00","last_reviewed_on":"2026-09-21T04:46:04.996939+00:00","identity":{"legal_name":"Bicara Therapeutics Inc.","display_name":"Bicara Therapeutics Inc.","headline":"Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts.","description":"Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transfo","ten_second_view":"This Company Profile publishes only Alpha's canonical identity and evidence-backed public leadership records. Unavailable fields are not inferred.","legal_form":"Not publicly asserted","incorporation":"Not publicly asserted","headquarters":"US","headquarters_address":{"locality":"Not publicly asserted","region":null,"country":"US"},"operating_presence":["US"],"website":"","cik":"0002023658","logo":"https://cdn.brandfetch.io/ticker/bcax/theme/dark/fallback/404/type/logo?c=1idgAB6rG5KFT5I7q5w","logo_source":"brandfetch","profile_mark":{"src":"https://cdn.brandfetch.io/ticker/bcax/theme/dark/fallback/404/type/logo?c=1idgAB6rG5KFT5I7q5w","alt":"Bicara Therapeutics Inc. logo","width":256,"height":256,"source":"brandfetch"}},"entity_status":{"ownership_type":"unknown","listing_status":"listed","label":"Public listing published","explanation":"The canonical public record includes at least one active security listing.","source_id":"alpha-canonical-company-record","reviewed_on":"2026-09-21T04:46:04.996939+00:00"},"security_listings":[{"ticker":"BCAX","exchange":"NASDAQ","exchange_display":"NASDAQ","mic":"XNAS","currency":"Unavailable","security_type":"equity","listing_status":"active","is_primary":true,"source_id":"alpha-canonical-company-record"}],"market_data":{"availability":"unavailable","endpoint":null,"source_label":null,"explanation":"Market data is not published in this Company Profile."},"profile_tags":["Canonical identity","Public leadership"],"trust_summary":"Canonical identity published; broader company intelligence is not asserted.","facts":[{"label":"Legal name","value":"Bicara Therapeutics Inc.","source_id":"alpha-canonical-company-record"},{"label":"Country","value":"US","source_id":"alpha-canonical-company-record"},{"label":"Sector","value":"Healthcare","source_id":"alpha-canonical-company-record"},{"label":"Industry","value":"Biotechnology","source_id":"alpha-canonical-company-record"}],"operating_model":{"eyebrow":"Operating record","title":"Published operating structure","units":[]},"governance":{"summary":"Only current, confirmed leadership roles with public evidence are included in the canonical projection.","boundary":"Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.","disclosures":[]},"alpha_opinion":{"status":"Not published","label":"No Alpha opinion published","explanation":"This identity record is not an Alpha rating, score, or investment opinion."},"report":{"status":"Not published","label":"No governed report published","explanation":"No governed company report is attached to this profile.","href":null},"actions":[],"related_records":[],"evidence":[{"id":"alpha-canonical-company-record","label":"Alpha canonical company public projection","href":"/api/public/companies/bicara-therapeutics-inc","source_type":"canonical_identity","supports":["Company identity","Published leadership","Entity status boundary"],"status":"published","reviewed_on":"2026-09-21T04:46:04.996939+00:00"}],"permissions":[{"label":"Public retrieval","allowed":true},{"label":"Agent retrieval","allowed":true},{"label":"Redistribution","allowed":false},{"label":"Model training","allowed":false},{"label":"Relationship pathfinding","allowed":false},{"label":"Direct contact","allowed":false}],"limitations":["Only explicitly published canonical company identity and current confirmed public roles are included.","Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.","Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.","This Company Profile is an identity and evidence record, not an Alpha rating."],"financials":{"kind":"financials","records":[],"limitation":"Only evidence-backed canonical_assertions already stored for this company. Empty records mean none are stored. Missing values are never invented.","source_table":"canonical_assertions","source_evidence_table":"canonical_source_records"},"ownership":{"kind":"ownership","records":[],"limitation":"Only evidence-backed canonical_assertions already stored for this company. Empty records mean none are stored. Missing values are never invented. 13F and N-PX are not beneficial ownership and are never projected here.","source_table":"canonical_assertions","source_evidence_table":"canonical_source_records"},"trust":{"schema_version":"alpha-profile-trust-v1","verification":{"schema_version":"alpha-verification-states-v1","state":"source_reported","identity_ownership":"unclaimed","assurance_level":null,"claim_state_counts":{"source_reported":14,"corroborated":0,"alpha_verified":0,"disputed":0,"superseded":0},"derivation":"claim_states+identity_ownership","summary":"Published claims are reported by public sources; none is Alpha verified. Profile ownership is unclaimed."},"aggregation":{"schema_version":"alpha-claim-aggregation-v1","published_claim_count":14,"under_review_claim_count":1,"owner_supplied_claim_count":0,"evidence_record_count":2,"distinct_source_count":2,"conflicts":[],"conflict_count":0,"headline_conflict_count":0,"internal_review_conflict_count":0,"contradiction_types":[],"headline_conflict_types":[],"verification":{"schema_version":"alpha-verification-states-v1","state":"source_reported","identity_ownership":"unclaimed","assurance_level":null,"claim_state_counts":{"source_reported":14,"corroborated":0,"alpha_verified":0,"disputed":0,"superseded":0},"derivation":"claim_states+identity_ownership","summary":"Published claims are reported by public sources; none is Alpha verified. Profile ownership is unclaimed."},"coverage":{"schema_version":"alpha-coverage-metric-v1","published_claims":14,"corroborated_claims":0,"sources":2,"distinct_sources":2,"role_claims":0,"last_reviewed_at":"2026-09-21T04:46:04.996939+00:00","observed_at":"2026-09-21T04:46:04.996939+00:00","freshness_days":0}},"rights":{"public_retrieval":"allowed","agent_retrieval":"allowed","redistribution":"not_granted","model_training":"not_granted","commercial_use":"not_specified","relationship_pathfinding":"not_granted","direct_contact":"not_granted"}},"projection":{"schema_version":"alpha-profile-projection-v5","entity":{"kind":"company","slug":"bicara-therapeutics-inc","canonical_url":"https://registry.alpha.ac/companies/bicara-therapeutics-inc"},"publication":{"published_at":"2026-09-21T04:46:04.996939+00:00","last_reviewed_at":"2026-09-21T04:46:04.996939+00:00","as_of":"2026-09-21T04:46:04.996939+00:00"},"representations":{"html":{"href":"https://registry.alpha.ac/companies/bicara-therapeutics-inc","media_type":"text/html"},"json":{"href":"https://registry.alpha.ac/api/public/companies/bicara-therapeutics-inc","media_type":"application/json"},"markdown":{"href":"https://registry.alpha.ac/companies/bicara-therapeutics-inc.md","media_type":"text/markdown"},"structured_data":{"embedded":true,"media_type":"application/ld+json"},"share_image":null},"permissions":{"public_retrieval":true,"agent_retrieval":true,"redistribution":false,"model_training":false,"relationship_pathfinding":false,"direct_contact":false}},"canonical_profile":{"schema_version":"alpha-company-profile-public-v1","slug":"bicara-therapeutics-inc","canonical_url":"https://registry.alpha.ac/companies/bicara-therapeutics-inc","as_of":"2026-09-21T04:46:04.996939+00:00","last_reviewed_at":"2026-09-21T04:46:04.996939+00:00","identity":{"legal_name":"Bicara Therapeutics Inc.","display_name":"Bicara Therapeutics Inc.","description":"Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transfo","jurisdiction":null,"country":"US","sector":"Healthcare","industry":"Biotechnology","website":null,"website_provenance":null,"logo_url":null,"logo_media":null,"status":"active","cik":"0002023658","entity_subtype":null,"legal_entity_status":null},"security_listings":[{"mic":"XNAS","ticker":"BCAX","currency":null,"exchange":"NASDAQ","sort_key":0,"valid_to":null,"confidence":0.95,"is_primary":true,"listing_id":"c1cb6df4-ff36-4cf3-984c-2d6828331d00","source_url":"https://www.sec.gov/files/company_tickers_exchange.json","valid_from":null,"observed_at":"2026-07-11T00:28:32+00:00","source_name":"sec_company_tickers_exchange","source_tier":1,"exchange_name":"NASDAQ","security_type":"equity","listing_status":"active","last_checked_at":"2026-09-02T01:48:40.989053+00:00"}],"market_data":{"availability":"unavailable","endpoint":null,"source_label":null,"explanation":"Market observations are unpublished. Listing identity remains available from the governed source set."},"index_memberships":[],"index_membership_history":[],"index_membership_contract":{"schema_version":"alpha-index-membership-public-v1","as_of_date":"2026-09-21","tracked_universe_complete":false,"permissions":{"public_retrieval":true,"agent_retrieval":false,"redistribution":false,"model_training":false},"limitations":["Only source-backed memberships with an explicit public redistribution basis are returned.","Absence from Alpha tracked indices does not establish absence from every market index.","Provider announcements and effective membership are represented as distinct states.","Alpha AI 100 is not published as a current public index membership."]},"leadership":{"board":[{"person_slug":"carolyn-ng-bcax","display_name":"Carolyn Ng","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2023-01-01","end_date":null,"verification_status":"confirmed","confidence":0.88,"evidence":{"document_title":"DEF 14A bcax-20260427.htm","source_url":"https://www.sec.gov/Archives/edgar/data/2023658/000162828026027320/bcax-20260427.htm","source_type":"sec_proxy","published_at":"2026-04-27T00:00:00+00:00","effective_date":"2026-04-27","last_checked_at":"2026-09-02T00:05:39.007738+00:00"},"headshot_url":null},{"person_slug":"christopher-bowden-bcax","display_name":"Christopher Bowden","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2024-01-01","end_date":null,"verification_status":"confirmed","confidence":0.88,"evidence":{"document_title":"DEF 14A bcax-20260427.htm","source_url":"https://www.sec.gov/Archives/edgar/data/2023658/000162828026027320/bcax-20260427.htm","source_type":"sec_proxy","published_at":"2026-04-27T00:00:00+00:00","effective_date":"2026-04-27","last_checked_at":"2026-09-02T00:05:39.007738+00:00"},"headshot_url":null},{"person_slug":"claire-mazumdar-bcax","display_name":"Claire Mazumdar","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2020-01-01","end_date":null,"verification_status":"confirmed","confidence":0.88,"evidence":{"document_title":"DEF 14A bcax-20260427.htm","source_url":"https://www.sec.gov/Archives/edgar/data/2023658/000162828026027320/bcax-20260427.htm","source_type":"sec_proxy","published_at":"2026-04-27T00:00:00+00:00","effective_date":"2026-04-27","last_checked_at":"2026-09-02T00:05:39.007738+00:00"},"headshot_url":null},{"person_slug":"jake-simson-bcax","display_name":"Jake Simson","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2023-01-01","end_date":null,"verification_status":"confirmed","confidence":0.88,"evidence":{"document_title":"DEF 14A bcax-20260427.htm","source_url":"https://www.sec.gov/Archives/edgar/data/2023658/000162828026027320/bcax-20260427.htm","source_type":"sec_proxy","published_at":"2026-04-27T00:00:00+00:00","effective_date":"2026-04-27","last_checked_at":"2026-09-02T00:05:39.007738+00:00"},"headshot_url":null},{"person_slug":"kate-haviland-bcax","display_name":"Kate Haviland","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2023-01-01","end_date":null,"verification_status":"confirmed","confidence":0.88,"evidence":{"document_title":"DEF 14A bcax-20260427.htm","source_url":"https://www.sec.gov/Archives/edgar/data/2023658/000162828026027320/bcax-20260427.htm","source_type":"sec_proxy","published_at":"2026-04-27T00:00:00+00:00","effective_date":"2026-04-27","last_checked_at":"2026-09-02T00:05:39.007738+00:00"},"headshot_url":null},{"person_slug":"kiran-mazumdar-shaw-bcax","display_name":"Kiran Mazumdar-Shaw","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2018-01-01","end_date":null,"verification_status":"confirmed","confidence":0.88,"evidence":{"document_title":"DEF 14A bcax-20260427.htm","source_url":"https://www.sec.gov/Archives/edgar/data/2023658/000162828026027320/bcax-20260427.htm","source_type":"sec_proxy","published_at":"2026-04-27T00:00:00+00:00","effective_date":"2026-04-27","last_checked_at":"2026-09-02T00:05:39.007738+00:00"},"headshot_url":null},{"person_slug":"michael-powell-bcax","display_name":"Michael Powell","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2024-01-01","end_date":null,"verification_status":"confirmed","confidence":0.88,"evidence":{"document_title":"DEF 14A bcax-20260427.htm","source_url":"https://www.sec.gov/Archives/edgar/data/2023658/000162828026027320/bcax-20260427.htm","source_type":"sec_proxy","published_at":"2026-04-27T00:00:00+00:00","effective_date":"2026-04-27","last_checked_at":"2026-09-02T00:05:39.007738+00:00"},"headshot_url":null},{"person_slug":"ryan-cohlhepp-bcax","display_name":"Ryan Cohlhepp","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2024-01-01","end_date":null,"verification_status":"confirmed","confidence":0.88,"evidence":{"document_title":"DEF 14A bcax-20260427.htm","source_url":"https://www.sec.gov/Archives/edgar/data/2023658/000162828026027320/bcax-20260427.htm","source_type":"sec_proxy","published_at":"2026-04-27T00:00:00+00:00","effective_date":"2026-04-27","last_checked_at":"2026-09-02T00:05:39.007738+00:00"},"headshot_url":null},{"person_slug":"scott-robertson-bcax","display_name":"Scott Robertson","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2023-01-01","end_date":null,"verification_status":"confirmed","confidence":0.88,"evidence":{"document_title":"DEF 14A bcax-20260427.htm","source_url":"https://www.sec.gov/Archives/edgar/data/2023658/000162828026027320/bcax-20260427.htm","source_type":"sec_proxy","published_at":"2026-04-27T00:00:00+00:00","effective_date":"2026-04-27","last_checked_at":"2026-09-02T00:05:39.007738+00:00"},"headshot_url":null}],"executives":[],"coverage":{"schema_version":"alpha-leadership-coverage-v1","board_roster_scope":"def_14a_current_directors","executive_roster_scope":"NOT_ASSERTED","neo_set_status":"NOT_ASSERTED","board_roster_complete":false,"neo_set_complete":false,"notes":["Empty executives is NOT_ASSERTED, not a complete named-executive-officer set.","Form 4 occupancy is not a DEF 14A board.","Unconfirmed current sec_proxy DEF 14A directors may project. Confirmed is not required.","Unconfirmed current executives with first-party issuer evidence (source_url + effective date) may project.","Company-page directors do not require people.public_profile_enabled.","Completeness compares the latest first-party roster with the public projection; a source older than 180 days is STALE.","Do not remap HONA to HON 0000773840. Do not merge XOM 0000034088 with 0002115436.","Person match is projection-only. Name-only Person merges are forbidden."],"completeness":{"reasons":["NO_LEADERSHIP_SOURCE"],"board_completeness":"NOT_REVIEWED","completeness_schema":"alpha-leadership-completeness-v1","executive_team_completeness":"NOT_REVIEWED"},"parser_bleed_excluded":true,"former_titles_excluded":true,"identity_merge_forbidden":true,"form4_occupancy_is_not_board":true}},"permissions":{"classification":"open_public_projection","public_retrieval":true,"agent_retrieval":true,"redistribution":false,"model_training":false,"relationship_pathfinding":false,"direct_contact":false},"limitations":["Only explicitly published canonical company identity and current confirmed public roles are included.","Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.","Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.","This Company Profile is an identity and evidence record, not an Alpha rating."],"structured_data":{"@context":["https://schema.org",{"alpha":"https://alpha.ac/ns/","indexMembership":"alpha:indexMembership","indexProvider":"alpha:indexProvider","indexMembershipStatus":"alpha:indexMembershipStatus","indexEffectiveDate":"alpha:indexEffectiveDate","indexAnnouncementDate":"alpha:indexAnnouncementDate","indexRemovalDate":"alpha:indexRemovalDate","lastVerifiedAt":"alpha:lastVerifiedAt","verificationStatus":"alpha:verificationStatus","evidence":"alpha:evidence"}],"@type":"ProfilePage","@id":"https://registry.alpha.ac/companies/bicara-therapeutics-inc#profile","url":"https://registry.alpha.ac/companies/bicara-therapeutics-inc","dateModified":"2026-09-21T04:46:04.996939+00:00","mainEntity":{"@type":"Organization","@id":"https://registry.alpha.ac/companies/bicara-therapeutics-inc#organization","legalName":"Bicara Therapeutics Inc.","name":"Bicara Therapeutics Inc.","description":"Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transfo","url":"https://registry.alpha.ac/companies/bicara-therapeutics-inc","addressCountry":"US","indexMembership":[],"member":[{"@type":"OrganizationRole","roleName":"Director","startDate":"2023-01-01","member":{"@type":"Person","name":"Carolyn Ng","url":"https://registry.alpha.ac/people/carolyn-ng-bcax"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2024-01-01","member":{"@type":"Person","name":"Christopher Bowden","url":"https://registry.alpha.ac/people/christopher-bowden-bcax"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2020-01-01","member":{"@type":"Person","name":"Claire Mazumdar","url":"https://registry.alpha.ac/people/claire-mazumdar-bcax"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2023-01-01","member":{"@type":"Person","name":"Jake Simson","url":"https://registry.alpha.ac/people/jake-simson-bcax"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2023-01-01","member":{"@type":"Person","name":"Kate Haviland","url":"https://registry.alpha.ac/people/kate-haviland-bcax"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2018-01-01","member":{"@type":"Person","name":"Kiran Mazumdar-Shaw","url":"https://registry.alpha.ac/people/kiran-mazumdar-shaw-bcax"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2024-01-01","member":{"@type":"Person","name":"Michael Powell","url":"https://registry.alpha.ac/people/michael-powell-bcax"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2024-01-01","member":{"@type":"Person","name":"Ryan Cohlhepp","url":"https://registry.alpha.ac/people/ryan-cohlhepp-bcax"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2023-01-01","member":{"@type":"Person","name":"Scott Robertson","url":"https://registry.alpha.ac/people/scott-robertson-bcax"}}]},"mainEntityOfPage":"https://registry.alpha.ac/companies/bicara-therapeutics-inc"},"financials":{"kind":"financials","records":[],"limitation":"Only evidence-backed canonical_assertions already stored for this company. Empty records mean none are stored. Missing values are never invented.","source_table":"canonical_assertions","source_evidence_table":"canonical_source_records"},"ownership":{"kind":"ownership","records":[],"limitation":"Only evidence-backed canonical_assertions already stored for this company. Empty records mean none are stored. Missing values are never invented. 13F and N-PX are not beneficial ownership and are never projected here.","source_table":"canonical_assertions","source_evidence_table":"canonical_source_records"}},"canonical_source":"aegis_canonical"}